top of page

®

Foveal LLP Independent Investment Research Foveal Research

Independent Investment Research

therapeutic topics_

Focus Research

JNJ/PTGX: JNJ2113: Concerns over upcoming (Q1) oral IL23 ANTHEM trial in Ulcerative Colitis

JNJ/PTGX: JNJ2113: Concerns over upcoming (Q1) oral IL23 ANTHEM trial in Ulcerative Colitis

JNJ/PTGX: JNJ2113: Concerns over upcoming (Q1) oral IL23 ANTHEM trial in Ulcerative Colitis

NOVN: Consensus missing large Fabhalta upside

NOVN: Consensus missing large Fabhalta upside

NOVN: Consensus missing large Fabhalta upside

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

WCLC: Hold you HARMONis: Keytruda safe from Summit

WCLC: Hold you HARMONis: Keytruda safe from Summit

WCLC: Hold you HARMONis: Keytruda safe from Summit

NOVN/ROG: Fabulous Fabhalta halts Piasky blue skies

NOVN/ROG: Fabulous Fabhalta halts Piasky blue skies

NOVN/ROG: Fabulous Fabhalta halts Piasky blue skies

Recent Research

INCY;PFE:ESMO Abstracts: IDO inhibitor underwhelms, PFE/MRCG anti PD-L1 appears modest

INCY;PFE:ESMO Abstracts: IDO inhibitor underwhelms, PFE/MRCG anti PD-L1 appears modest

INCY;PFE:ESMO Abstracts: IDO inhibitor underwhelms, PFE/MRCG anti PD-L1 appears modest

ESMO Abstracts out... With new Abstracts from the upcoming ESMO/ECC cancer conference just published we take a critical first look at the...

Sep 12, 2015

New data at WCLC may shrink PD-1 lung cancer opportunity. Bristol still leads but Roche’s PD-L1 may

New data at WCLC may shrink PD-1 lung cancer opportunity. Bristol still leads but Roche’s PD-L1 may

New data at WCLC may shrink PD-1 lung cancer opportunity. Bristol still leads but Roche’s PD-L1 may

Updated data presented this week at the World Conference on Lung cancer revealed Bristol’s anti PD1 immunotherapy Opdivo failed to...

Sep 9, 2015

JNJ/PTGX: JNJ2113: Icotrokinra ANTHEM-Ulercative Colitis efficacy similar to oral competitors

Mar 10

JNJ/PTGX: JNJ2113: Concerns over upcoming (Q1) oral IL23 ANTHEM trial in Ulcerative Colitis

Feb 11

NOVN: Consensus missing large Fabhalta upside

NOVN: Consensus missing large Fabhalta upside

NOVN: Consensus missing large Fabhalta upside

Dec 11, 2024

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

Dec 11, 2024

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

Oct 3, 2024

WCLC: Hold you HARMONis: Keytruda safe from Summit

Sep 22, 2024

NOVN/ROG/IONS/CALTX/AZN: Factor B lacking the X Factor in IgAN

Aug 20, 2024

NOVN/ROG: Fabulous Fabhalta halts Piasky blue skies

Jul 28, 2024

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

Jul 1, 2024

MRNA/MRK: ASCO cancer vaccine data does not address pre-treatment imbalances that may be driving result

Jun 18, 2024

Archive

Search By Tags

Follow Us

Bloomberg: FOVL <go>

ThomsonReuters

FactSet

Captial IQ

bottom of page